Angioplasty for the revascularization of blocked coronary arteries gave way in the evolution of clinical practice to the adjunctive use of bare metal coronary stents, but due to a high frequency of restenosis bare metal stents gave way to drug-eluting stents (DESs) in 2003 (J&J/CYPHER, followed in 2004 by Boston Scientific’s TAXUS, and soon followed by DES products from Medtronic, Abbott Vascular and a host of others). While issues of late stage thrombosis in DESs were a brief setback for their sales in 2005-06, they have only modestly recovered, stimulating the further development of technologies to result in revascularized lumens with a minimum of complications (while also giving bare metal stents a persistent toehold on the coronary stent market). Emerging stent or other anti-restenosis technologies in percutaneous coronary intervention include a range of absorbable stents, as well as drug-eluting balloons.
Needless to say (but we will anyway), the coronary stent market (as well as the broader market for treatment of coronary artery disease, encompassing a variety of coronary artery bypass technologies and procedures) remains a dynamic arena for medtech development.
Drawn from Report #C245: "Worldwide Coronary Stents Market, 2008-2017."